U.S. Markets closed

RedHill Biopharma Ltd. (RDHL)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
7.17-0.04 (-0.55%)
At close: 4:00PM EDT
7.17 0.00 (0.00%)
After hours: 05:13PM EDT

RedHill Biopharma Ltd.

21 Ha’arba’a Street
Tel Aviv 6473921
Israel
972 3 541 3131
http://www.redhillbio.com

Sector(s)Healthcare
IndustryDrug Manufacturers—Specialty & Generic
Full Time Employees182

Key Executives

NameTitlePayExercisedYear Born
Mr. Dror Ben-AsherCo-Founder, Chairman & CEO555.97kN/A1966
Mr. Micha Ben-ChorinChief Financial Officer418.05kN/A1969
Mr. Gilead RadayChief Operating Officer388.25kN/A1975
Mr. Adi FrishChief Corp. & Bus. Devel. Officer407.21kN/A1970
Mr. Rick D. ScruggsChief Commercial Officer, Head of US Operations & Director577.99kN/A1960
Dr. June S. AlmenoffChief Scientific OfficerN/AN/A1957
Mr. Ben MartieVP, Legal AffairsN/AN/AN/A
Ms. Shani MauriceVP of Bus. Devel. & CommunicationsN/AN/AN/A
Ms. Valerie GraceffaVP of SalesN/AN/AN/A
Mr. Rob JacksonSr. VP of Sales & MarketingN/AN/AN/A
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focused on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with chronic non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its clinical late-stage investigational development programs include RHB-204, which is in Phase 3 study for pulmonary nontuberculous mycobacteria infections; opaganib (Yeliva), an SK2 selective inhibitor, which has completed Phase 2 study to treat patients with SARS-CoV-2 severe COVID-19 pneumonia, in Phase 1/2a study to treat advanced unresectable cholangiocarcinoma, and in investigator-sponsored Phase 2 study to treat prostate cancer; RHB-104, which is in Phase 3 studies for Crohn's disease; RHB-102 (Bekinda) that is in Phase 3 studies for acute gastroenteritis and gastritis, and has completed Phase 2 studies for irritable bowel syndrome with diarrhea; RHB-107, which is in Phase 2/3 study to treat outpatients infected with COVID-19 disease, and Phase 2a study to treat advanced unresectable cholangiocarcinoma, as well as has completed Phase 2 study to treat gastrointestinal and other solid tumors; and RHB-106, an encapsulated formulation for bowel preparation, which has completed Phase 2a study. The company was incorporated in 2009 and is headquartered in Tel Aviv, Israel.

Corporate Governance

RedHill Biopharma Ltd.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.